Overview

Our client is a UK-based clinical stage immune – oncology company that has identified a novel and valuable cancer target marker that only appears on the cell surface of a wide range of cancers including Lung, Breast, Colorectal, and Prostate, but is absent in healthy tissue. The company has shown that the marker has been identified on the surface of cancerous cells in 36 of the 36 tested cell lines to date, on the NCI60 panel. Drugs targeting nfP2X7 have the potential to treat a wide variety of cancers, with minimal side effects, and in doing so win a significant place in the forecast US$41 billion p.a. market.

Our client has developed a CAR-T immunotherapy targeting the nfP2X7 marker. Generally speaking, CAR-T therapy is a form of immunotherapy that uses specially altered T cells to fight cancer. With CAR-T, white blood cells are removed and “trained" to recognise and kill cancer cells bearing the nfP2X7 target.

Collaborations during 2018/9 have yielded some compelling data and our clients CAR-T therapy has achieved consistent cell killing results. Other pipeline assets include antibody therapy BIL03s, BIL04s and topical application of BIL010t for non-melanoma skin cancer lesions.

Funds raised are to be utilised to progress the company’s:

•        3 clinical trials for the CAR-T Antibody BIL03s and Antibody BIL04s

•        Undertake a India based clinical trial

•        Progress marketing approval applications with the FDA in the USA, the National Medical Products Administration (NMPA) in China and other registrations for the rest of world on the back of successfully completed registrational clinical trials

Our client has a very solid Intellectual Property position holding well over 185 patents across fourteen patent families surrounding nfP2X7

Another opportunity is accessing the Indian domestic market, the company is also seeking a suitably qualified Joint Venture party with whom they can work with to undertake Indian domestic clinical trials and then distribution throughout china. The company is most willing to open a research, development and commercial operations office in India, with the goal of eventually listing this business on the stock exchange.

The company comprises; very experienced Executive Management/Board directors, and a Clinical Advisory Board comprising World Key Opinion makers, including the Chairman who is the 2018 Nobel Prize Winner in Chemistry.

Significant potential exits for the company to utilise its technology through acquiring an FDA Rare Pediatric Priority Review Voucher – market Value 2015-2017 USD$125-$350 million with supporting trials offered through two investigator initiated trials at Universitätsklinikum Tübingen - Children's Hospital and National Cancer Centre Singapore (no cost to the company).

Competitive Advantages - No current cancer therapeutics have achieved the potential breadth of efficacy attributed to this immune system response solution.

Exit Strategy – IPO planned for 18 months, there is considerable upside from investing in this company before the IPO is completed.